Table 1 Characteristics of the study patients
Characteristics | All patients (N = 140) |
|---|---|
Male gender, n (%) | 109 (77.9%) |
EOT Age, years | 49.1 (39.2, 57.5) |
EOT anti-HBe-positive, n (%) | 131 (93.6%) |
EOT HBsAg, log IU/mL | 2.79 (2.13, 3.12) |
EOT ALT, U/L | 22 (16.5, 34) |
EOT AFP, ng/ml | 2.7 (1.97, 3.41) |
Pretreatment HBeAg-positive, n (%) | 39 (27.9%) |
Pretreatment anti-HBe-positive, n (%) | 100 (71.4%) |
Pretreatment viral DNA, log IU/ml | 6.21 (4.53, 7.67) |
Pretreatment ALT, U/L | 154 (95, 451) |
On-therapy duration, month | 36.6 (36.4, 37.0) |
Off-therapy follow-upa, month | 19.9 (10.6, 25.3) |
Patients received Entecavir | 125 (89.3%) |
Patients received Tenofovir, | 9 (6.4%) |
Patients received Lamivudine or Telbivudine | 6 (4.2%) |